From what I heard in the interview, Rebecca's comment on scarcity of neurosurgeons was about the trials themselves, not the final product.
Given this scarcity, the trials become not only expensive but logistically challenging to plan and conduct.
Her feeling seems to be that CHM's limited resources are better focused on the other trials... at least for now.
- Forums
- ASX - By Stock
- CHM
- Webinar 17/06/24
Webinar 17/06/24, page-26
Featured News
Add CHM (ASX) to my watchlist
|
|||||
Last
2.0¢ |
Change
0.002(11.1%) |
Mkt cap ! $17.25M |
Open | High | Low | Value | Volume |
1.9¢ | 2.1¢ | 1.9¢ | $56.44K | 2.801M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 1655923 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 1520755 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 1655923 | 0.020 |
7 | 1118235 | 0.019 |
4 | 1361662 | 0.018 |
8 | 1038053 | 0.017 |
13 | 3864022 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 208333 | 1 |
0.022 | 710000 | 4 |
0.023 | 335000 | 3 |
0.024 | 673304 | 5 |
0.025 | 717500 | 2 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online